Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Officials Urge Meningitis Shots at University of Oregon

By Drug Discovery Trends Editor | March 20, 2015

More than half of the undergraduates at the University of Oregon have not been vaccinated against meningitis, despite the fact that one student has died and five others have been sickened since January.

Public health officials are appealing to parents to get the job done during spring break.

HOW MANY STUDENTS REMAIN UNVACCINATED?

About 13,000 of the university’s 22,000 undergraduates, considered at highest risk for the disease, have yet to be vaccinated.

WHAT’S THE SCHOOL DOING?

Around campus there are posters featuring smiling student athletes showing off the arm where they were vaccinated and sporting a green or gold adhesive bandage with the school logo.

In early March, vaccinations were offered at the university’s basketball arena, and students are now being urged to go to local pharmacies. Emails have been sent to parents. The university has worked with insurance companies to make sure the vaccinations are covered. Vaccines, which cost about $170 each, have been donated for students without insurance.

Students are being offered two different types of new vaccines that target the B strain of meningococcal disease, which can rapidly develop into a blood infection, or meningitis, which infects the lining of the brain or spinal cord. One vaccine offers two shots over a month. The other offers three shots over six months.

Students who have been in close contact with those who came down with the disease are given an antibiotic to kill bacteria that may be currently in their nasal passages.

More than half of the undergraduates at the University of Oregon have not been vaccinated against meningitis, despite the fact that one student has died and five others have been sickened since January.

Public health officials are appealing to parents to get the job done during spring break.

WHY SO MANY HOLDOUTS?

A university official said the administration is working to overcome young people’s tendency to ignore preventative health care. The meningitis vaccine is not mandatory.

“We expect this is going to take time to continue to have a steady increase in the number of students vaccinated on our campus,” university spokeswoman Julie Brown said.

OUTBREAKS OFTEN AFFECT THE YOUNG

Meningococcal disease is rare, with 1,000 to 2,000 cases per year among the U.S. population of 300 million people. But it tends to erupt in outbreaks among young people under stress in a new place, such as college campuses and military boot camp, where they are exposed to diseases for which they have no immunity, said Dr. Patrick Luedtke, Lane County public health officer.

Between 7 and 10 percent of people who get the disease die, and about a third will have long-lasting damage, such as deafness, seizures, and amputations, he added.

The latest case at Oregon is a 20-year-old sophomore man who lives off campus, and he went to an outpatient clinic with flu-like symptoms. There have been six cases since Jan. 13. One has died, an 18-year-old freshman woman on the acrobatics and tumbling team.

OFFICIAL FRUSTRATION

“It is not possible to have been on the University of Oregon campus the last several weeks and not know there are meningococcal cases,” Dr. Paul Cieslak, director of infectious diseases for the Oregon Public Health Division, said Thursday in Portland, Oregon. “And the vaccine is available. Messaging is ubiquitous. Yet there are 13,000 students who didn’t get vaccinated.”

Cieslak said hundreds or even thousands of students have likely been exposed, though only some will come down with the disease.

Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

In door grow hemp. Cannabis at the beginning of flowering. Legal Marijuana cultivation in the home. Green background of leaves. Young cannabis plant. Medicinal indica with CBD.
Why Schedule III cannabis could be a win for Big Pharma
Red blood cells macro over red eritrosit background. Concept of blood cells count, medicine and healthcare. 3d rendering mock up
Platelet-inspired nanoparticle delivers drugs directly where they are needed
Lilly’s triple agonist delivers up to 71.2 lbs of weight loss in Phase 3 trial
China’s biopharma sector enters ‘innovation 2.0’ era
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE